


This listing of claims will replace all prior versions, and listings, of claims in the application:


**Listing of Claims:**

Claim 1 (previously presented): A process for synthesizing a dihydroindole C-ring of a CC-1065/duocarmycin analog, the dihydroindole C-ring of a CC-1065/duocarmycin analog being represented by the following structure:



the process comprising the following steps:

Step A: allylating an *ortho*-halo-2-aminonaphthaline with 1,3-dichloropropene for forming a vinyl chloride, the *ortho*-halo-2-aminonaphthaline being represented by the following structure:




wherein:

R<sup>1</sup> is a hydroxyl protecting group; and

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are radicals independently selected from the group consisting of hydrogen, alkyl(C1-C6), alkoxy, cyano, and arylalkoxy; and

X is a halide selected from the group consisting of bromine and iodine; and the vinyl chloride is represented by the following structure:



Step B: cyclizing the vinyl chloride of said step A for forming the dihydroindole C-ring of the CC-1065 /duocarmycin analog.

Claims 2-18 (cancelled)

Claim 19 (previously presented): A process according to claim 1 wherein, in said Step A, the *ortho*-halo-2-aminonaphthaline is an *ortho*-bromo-2-aminonaphthaline.

Claim 20 (previously presented): A process according to claim 1 wherein, in said Step A, the *ortho*-halo-2-aminonaphthaline is an *ortho*-iodo-2-aminonaphthaline.

Claim 21 (cancelled)


Claim 22 (previously presented): A process according to claim 1 wherein, in said Step A, said allylation is catalyzed by the addition of a catalytic amount of tetra-*n*-butylammonium iodide.

Claim 23 (previously presented): A process according to claim 1 wherein, in said Step B, said cyclization is performed with an addition of tri-*n*-butyltin hydride.


Claim 24 (previously presented): A process according to claim 23 wherein, in said Step B, said cyclization is catalyzed by the addition of a catalytic amount of AIBN.

Claim 25 (previously presented): A process according to claim 24 wherein, in said Step B, said cyclization is performed using toluene as the solvent.

Claim 26 (previously presented): A process according to claim 1 wherein, in said Step A, the vinyl chloride is represented by the following structure:




in said Step B, the dihydroindole C-ring of the CC-1065/duocarmycin analog is represented by the following structure:




Claim 27 (previously presented): A process according to claim 1 wherein:

in said Step A, the vinyl chloride is represented by the following structure:




in said Step B, the dihydroindole C-ring of the CC-1065 / duocarmycin analog is represented by the following structure:




Claims 28-31 (cancelled)

Claim 32 (previously presented): A process for synthesizing a dihydroindole C-ring of a CC-1065/duocarmycin analog, the dihydroindole C-ring of a CC-1065/duocarmycin analog being represented by the following structure:




the process comprising the following steps:

Step A: allylating an *ortho*-haloaniline with 1,3-dichloropropene for forming a vinyl chloride, the *ortho*-haloaniline being represented by the following structure:



the vinyl chloride being represented by the following structure:



Step B: cyclizing the vinyl chloride of said step A for forming the dihydroindole C-ring of the CC-1065 / duocarmycin analog.